Sinolink Securities: Pharmaceutical prosperity in the third quarter hovers at the bottom, focusing on the improvement prospects for the next 25 years.

In the third quarter, due to internal adjustments in the healthcare sector, changes in the consumer environment, and some medical insurance cost control policies still being implemented, the business climate continued to bottom out in the Q3 report, with a slower rebound than expected.

Zhitong FinanceNov 4 01:30 ET

Hong Kong stocks are moving | The morning trading of Coland Biotech-B (06990) surged more than 8% with the application for Laxusathuzumab monoklonal antibody new drug being accepted, there may be multiple products launched recently.

Hansoh Bio-B (06990) rose more than 8% in the morning, as of press time, up 5.65% to 187 Hong Kong dollars, with a turnover of 35.4396 million Hong Kong dollars.

Zhitong FinanceNov 3 21:26 ET

Sichuan Kelun-Biotech Biopharmaceutical Engages Downstream Distributor; Seller

MT NewswiresNov 1 06:13 ET

Hong Kong Stock Exchange Exploration | Healthy World Technology-B: LuX-Valve Plus TRAVEL II one-year clinical follow-up results to be released at the 2024 American Washington Congress of Cardiology through the catheter.

CH Energy Eng (03996) controlling shareholder received financial support for shareholding in A shares; following Takeda's FRUQUINTINIB (呋喹替尼/fruquintinib) sales exceeding 0.2 billion US dollars, Hutchmed (China) (00013) will receive the first milestone payment.

Zhitong FinanceOct 31 11:07 ET

Private Companies Among Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s (HKG:6990) Largest Stockholders and Were Hit After Last Week's 11% Price Drop

Simply Wall StOct 30 21:55 ET

Concord Medical-B (06990.HK): The new drug application for the core product Lukan Satumab monotherapy (SAC-TMT) has been accepted by the National Medical Products Administration.

Gelonghui Oct. 31st | Kolonbo Tai Biotechnology-B (06990.HK) released an announcement that the new drug application (NDA) based on the positive results of the OptiTROP-Lung04 pivotal Phase III study of lucanituzumab tesirine (sac-TMT, formerly SKB264/MK-2870) has been accepted by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).

Gelonghui FinanceOct 30 19:27 ET